All In Biotech

Drug Trial Radar · NCT00056056

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides

Last checked: Nov 20, 2026Latest source record: Jul 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

93

Actual

Start

Jan 2003

Primary completion

May 2010

Study completion Jun 2011

Sponsor

Sponsor type
Research network
First posted
Mar 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy is more effective with or without bexarotene in treating mycosis fungoides. PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.

Conditions

  • Lymphoma

Interventions

  • bexaroteneDrug

    The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first

  • methoxypsoralenDrug

    The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.

  • UV light therapyProcedure

    Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (complete clinical response [CCR) and partial response [PR])Time frame: 35 months after first patient in

Locations

28 sites in 13 countries. Site status is shown where the registry gives one.

  • Karl-Franzens-University Graz

    Graz, Austria

  • Allgemeines Krankenhaus - Universitatskliniken

    Vienna, Austria

  • Ghent University

    Ghent, Belgium

  • U.Z. Gasthuisberg

    Leuven, Belgium

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Centre Hospitalier Universitaire Henri Mondor

    Créteil, France

  • CHR Hotel Dieu

    Nantes, France

  • Klinikum der Stadt Mannheim

    Mannheim, Germany

  • Klinikum Minden

    Minden, Germany

  • Hospital Universitario Insular de Gran Canaria

    Tübingen, Germany

  • Southwest German Cancer Center at Eberhard-Karls-University

    Tübingen, Germany

  • Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg

    Würzburg, Germany

  • Semmelweis University

    Budapest, Hungary

  • County Hospital

    Kaposvár, Hungary

  • Rabin Medical Center - Beilinson Campus

    Petah Tikva, Israel

  • Spedali Civili di Brescia

    Brescia, Italy

  • Istituto Dermopatico Dell' Immacolata

    Rome, Italy

  • Universita di Torino

    Turin, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Hospital de la Santa Cruz i Sant Pau

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Nuestra Senora de la Candelaria

    Santa Cruz de Tenerife, Spain

  • UniversitaetsSpital Zuerich

    Zurich, Switzerland

  • St. Thomas' Hospital

    London, England, United Kingdom

  • Royal Infirmary of Edinburgh at Little France

    Edinburgh, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.